Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Androgen Replacement Therapy or low testosterone therapy is commonly called hormone replacement therapy for men. It is designed to counteract the effects of reduced activity in the gonads or hypogonadism. Hypogonadism in men is a clinical syndrome which results in the failure of the testes to produce physiological levels of testosterone. The primary reason for hypogonadism may be a problem with the testes. The secondary reason is a problem with the hypothalamus or pituitary gland or both primary and secondary. Primary hypogonadism is caused due to genetic abnormalities, testicular trauma, orchitis, radiation treatment or chemotherapy, while secondary hypogonadism is caused due to genetic abnormalities of pituitary gland and hypothalamus. Testosterone injections, implants, gels, creams and oral medications are used for treatment of hypogonadism. Patients can use the medication as per their convenience.

The androgen replacement therapy market is estimated to be valued at US$ 1,736.9 million in 2020 and is expected to exhibit a CAGR of 3.7% during the forecast period (2020-2027).

Fig. 1. Androgen Replacement Therapy Market Share (%) Analysis in Terms of value, By Product Type, 2020

Androgen Replacement Therapy  | Coherent Market Insights

The increasing prevalence of hypogonadism and product launches are expected to drive growth of the androgen replacement therapy market

The growing prevalence of hypogonadism in adult men worldwide is expected to drive growth of the androgen replacement therapy market. According to the European Association of Urology: 2016 report, among middle-aged men, the incidence of hypogonadism varies from 2.1% to 12.8%. In Europe, the incidence of low testosterone and symptoms of hypogonadism in men in the age group of 40 to 79 varies from 2.1% to 5.7%. Hypogonadism is more prevalent in older men, in men with obesity, those with co-morbidities, and in men with a poor health status. Furthermore, according to the Therapeutics Advances of Urology Journal: 2016, testosterone was one of the most widely prescribed medications in the U.S. in 2011. This has resulted in growth of androgen replacement therapy from US$ 18 million in 1980 to US$ 1.6 billion in 2011 which was a five-fold increase.

Moreover, products launches by market players are expected to accelerate the androgen replacement therapy market growth in the near future. For instance, in April 2019, Israeli generics company, Teva Pharmaceutical Industries (Teva), announced the launch of generic versions of AndroGel (testosterone gel) 1.62% CIII and VESIcare (solifenacin succinate) tablets, 5 mg and 10 mg, in the U.S. Testosterone gel 1.62% CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, which include congenital or acquired primary hypogonadism and congenital or acquired hypogonadotropic hypogonadism.

Androgen Replacement Therapy Market - Restraints

However, growth of the androgen replacement therapy market may be hampered owing to the increasing product recalls of testosterone products in the market. For instance, in August 2018, the U.S. subsidiary of Sun Pharmaceutical Industries Ltd recalled more than 5,215 units of 10 ml vials of testosterone cypionate injections, in the strength of 200 mg/ml from the U.S. market, the latest enforcement report of recall was ordered by the U.S. Food and Drug Administration (US FDA). According to the U.S.FDA report, the ongoing voluntary nationwide recall is a Class II recall, initiated in a situation. The product was recalled due to the possibility of it causing temporary or medically reversible adverse health consequences.

Androgen Replacement Therapy Market – Regional Analysis

North America accounted for the largest share in the androgen replacement therapy market, in 2019 owing to the increasing number of product launches in the U.S. For instance, in October 2018, the Perrigo Company Plc. announced the launch of an AB-rated generic version of Androgel Topical Gel, 1.62% (20.25mg testosterone/1.25g packet, 40.5mg testosterone/2.5g packet, and 20.25mg/1.25g actuation pump). At generic market formation, an unrelated third party has launched an authorized generic version. Androgel Topical Gel, 1.62% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Furthermore, major companies in the market are focusing on acquiring license agreements to gain commercial rights for a particular country which is expected to drive growth of the androgen replacement therapy market in Asia Pacific. For instance, in December 2016, Acerus Pharmaceuticals Corporation announced the signing of an agreement granting exclusive right to market NATESTO in South Korea to Hyundai Pharm Co. Ltd., a South Korean pharmaceutical company. NATESTO is the first and only testosterone nasal gel for androgen replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).

Report Coverage Details
Base Year: 2019 Market Size in 2019: US $ 1,736.9 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 3.7% 2027 Value Projection: US $ 2,317.7 Mn
Geographies covered:
  • North America: U.S.,Canada.
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, UK, Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Product Type: Creams/Gels, Patches, Injections, Implants, Orals (Tablets/Capsules/Gum)
  • By Active Ingredient Type: Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, Testosterone Cypionate
  • By Distribution Channel: Hospitals Pharmacie, Retail Pharmacies, Online Pharmacies
Companies covered (18):

AbbVie, Inc., Allergan Plc., Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International Plc., Mylan N.V., Novartis International AG, Pfizer, Inc., Clarus Therapeutics, Ferring Holding SA, Perrigo Company Plc., Acerus Pharmaceuticals Corporation, Upsher-Smith Laboratories, LLC, Dr. Reddy's Laboratories, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., and Par Pharmaceutical.

Growth Drivers:
  • The increasing prevalence of hypogonadism
  • The increasing number of product approvals and launches
Restraints & Challenges:
  • Frequent product recalls
  • Increasing adverse effects of Testosterone

Fig.2 Androgen Replacement Therapy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Androgen Replacement Therapy  | Coherent Market Insights

Androgen Replacement Therapy Market - Competitive Landscape

Key players operating in the androgen replacement therapy market are AbbVie, Inc., Allergan Plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International Plc, Mylan N.V., Novartis International AG, Pfizer, Inc., Clarus Therapeutics, Ferring Holding SA, Perrigo Company Plc, Acerus Pharmaceuticals Corporation, Upsher-Smith Laboratories, LLC, Dr. Reddy's Laboratories, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., and Par Pharmaceutical.

Androgen Replacement Therapy Market Report Coverage

Androgen replacement therapy (ART), often referred to as testosterone replacement therapy (TRT), is a form of hormone therapy, in which androgens, often testosterone, are replaced. ART is often prescribed to counter the effects of male hypogonadism. It typically involves the administration of testosterone through injections, skin creams, patches, gels, or subcutaneous pellets. Testosterone replacement therapy is a promising technology for improving symptoms of hypogonadism and to raise the testosterone level. Furthermore, benefits related to application of testosterone replacement therapy include an increase in muscle tissue, overall surge in energy, and significant decrease in depression symptoms.

Market Dynamics

The androgen replacement therapy market is expected to witness growth during the forecast period owing to the increasing number of product launches in the market. For instance, in April 2019, Lupin announced the launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation) after receiving an approval from the U.S. Food and Drug Administration (FDA). The testosterone gel is the generic equivalent of AbbVie Inc’s AndroGel, 1.62%. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism.

However, the side effects caused due to androgen replacement therapy are expected to hamper the androgen replacement therapy market growth. The side effects from the androgen replacement therapy are chest pain, shortness of breath or trouble breathing, weakness in one part or one side of the body, slurred speech, sleep apnea, increased cholesterol levels, and increased blood pressure. For instance, in 2015, the U.S.FDA issued a warning about potential cardiovascular risks such as heart attack and stroke resulting from testosterone therapy.

Key features of the study:

  • This report provides in-depth analysis of the global androgen replacement rherapy market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global androgen replacement therapy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study are AbbVie, Inc., Allergan Plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International Plc, Mylan N.V., Novartis International AG, Pfizer, Inc., Clarus Therapeutics, Ferring Holding SA, Perrigo Company Plc, Acerus Pharmaceuticals Corporation, Upsher-Smith Laboratories, LLC, Dr. Reddy's Laboratories, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., and Par Pharmaceutical.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global androgen replacement therapy market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for androgen replacement therapy market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Androgen Replacement Therapy Market, By Product Type:
    • Creams/Gels
    • Patches
    • Injections
    • Implants
    • Orals Tablets/Capsules/Gums
  • Global Androgen Replacement Therapy Market, By Active Ingredient Type:
    • Testosterone
    • Methyl Testosterone
    • Testosterone Undecanoate
    • Testosterone Enanthate
    • Testosterone Cypionate
  • Global Androgen Replacement Therapy Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Androgen Replacement Therapy Treatment Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Product Type:
        • Creams/Gels
        • Patches
        • Injections
        • Implants
        • Orals Tablets/Capsules/Gums           
      • By Active Ingredient Type:
        • Testosterone
        • Methyl Testosterone
        • Testosterone Undecanoate
        • Testosterone Enanthate
        • Testosterone Cypionate
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Product Type:
        • Creams/Gels
        • Patches
        • Injections
        • Implants
        • Orals Tablets/Capsules/Gums           
      • By Active Ingredient Type:
        • Testosterone
        • Methyl Testosterone
        • Testosterone Undecanoate
        • Testosterone Enanthate
        • Testosterone Cypionate
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Product Type:
        • Creams/Gels
        • Patches
        • Injections
        • Implants
        • Orals Tablets/Capsules/Gums           
      • By Active Ingredient Type:
        • Testosterone
        • Methyl Testosterone
        • Testosterone Undecanoate
        • Testosterone Enanthate
        • Testosterone Cypionate
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Product Type:
        • Creams/Gels
        • Patches
        • Injections
        • Implants
        • Orals Tablets/Capsules/Gums           
      • By Active Ingredient Type:
        • Testosterone
        • Methyl Testosterone
        • Testosterone Undecanoate
        • Testosterone Enanthate
        • Testosterone Cypionate
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Product Type:
        • Creams/Gels
        • Patches
        • Injections
        • Implants
        • Orals Tablets/Capsules/Gums           
      • By Active Ingredient Type:
        • Testosterone
        • Methyl Testosterone
        • Testosterone Undecanoate
        • Testosterone Enanthate
        • Testosterone Cypionate
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Product Type:
        • Creams/Gels
        • Patches
        • Injections
        • Implants
        • Orals Tablets/Capsules/Gums           
      • By Active Ingredient Type:
        • Testosterone
        • Methyl Testosterone
        • Testosterone Undecanoate
        • Testosterone Enanthate
        • Testosterone Cypionate
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • AbbVie, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Allergan Plc
    • Bayer AG
    • Endo Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Kyowa Kirin International Plc
    • Mylan N.V.
    • Novartis International AG
    • Pfizer, Inc.
    • Clarus Therapeutics
    • Ferring Holding SA
    • Perrigo Company Plc
    • Acerus Pharmaceuticals Corporation
    • Upsher-Smith Laboratories, LLC
    • Reddy's Laboratories
    • Bausch Health Companies Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Par Pharmaceutical

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Active Ingredient Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Regulatory Scenario
    • Reimbursement Scenario
    • New Product Launches/Approvals
    • Collaborations & Partnerships
    • Mergers & Acquisitions
    • PEST Analysis
  4. Global Androgen Replacement Therapy Market, By Product Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Creams/Gels
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Patches
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Injections
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Implants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Oral Tablets/Capsules/Gums
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  5. Global Androgen Replacement Therapy Market, By Active Ingredient Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Testosterone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Methyl Testosterone
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Testosterone Undecanoate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Testosterone Enanthate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Testosterone Cypionate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Androgen Replacement Therapy Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Androgen Replacement Therapy Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Active Ingredient Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Active Ingredient Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Active Ingredient Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Active Ingredient Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Active Ingredient Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Active Ingredient Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • AbbVie, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Allergan Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Endo Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Kyowa Kirin International Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Clarus Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Ferring Holding SA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Perrigo Company Plc
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Acerus Pharmaceuticals Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Upsher-Smith Laboratories, LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Reddy's Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bausch Health Companies Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Par Pharmaceutical
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies

  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 35 market data tables and 33 figures on "Global Androgen Replacement Therapy Market” - Forecast to 2027”

Frequently Asked Questions

The CAGR of the androgen replacement therapy market is 3.7% during the forecast period (2020-2027).
The value of global market for androgen replacement therapy market is US$ 1,736.9 million in 2020.
prominent players in the androgen replacement therapy market across the globe are AbbVie, Inc., Allergan Plc., Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Clarus Therapeutics, Ferring Holding SA, Perrigo Company Plc., Acerus Pharmaceuticals Corporation, Upsher-Smith Laboratories, LLC, and Dr. Reddy's Laboratories.
The androgen replacement therapy market is expected to be valued at US$ 2,317.7 in 2027.
North America held the largest share in the androgen replacement therapy market in 2019.
The rising prevalence of hypogonadism in males, and the increasing number of product approvals and launches are expected to drive growth of the androgen replacement therapy market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner